atrasentan has been researched along with zibotentan in 7 studies
Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (zibotentan) | Trials (zibotentan) | Recent Studies (post-2010) (zibotentan) |
---|---|---|---|---|---|
358 | 41 | 108 | 67 | 18 | 46 |
Protein | Taxonomy | atrasentan (IC50) | zibotentan (IC50) |
---|---|---|---|
Endothelin-1 receptor | Homo sapiens (human) | 0.021 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carducci, MA; Jimeno, A | 1 |
Lalich, M; Liu, G; McNeel, DG; Wilding, G | 1 |
Beuzeboc, P; Neuzillet, Y; Villers, A | 1 |
Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P | 1 |
Ding, Y; Feng, NH; Jiang, WY; Qiao, D; Shao, N; Wang, JL; Wang, Y; Wu, Y; Zhang, SG; Zhang, XX | 1 |
Chen, M; He, ZH; Qi, P; Song, RX; Wang, ZP; Zhang, LX | 1 |
6 review(s) available for atrasentan and zibotentan
Article | Year |
---|---|
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endothelin Receptor Antagonists; Female; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2006 |
Endothelin receptor antagonists in cancer therapy.
Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides | 2007 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Targeting the endothelin axis in prostate carcinoma.
Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2012 |
Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer.
Topics: Atrasentan; Disease-Free Survival; Endothelin Receptor Antagonists; Humans; Immunotherapy; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Pyrrolidines; Tissue Extracts | 2013 |
A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
1 other study(ies) available for atrasentan and zibotentan
Article | Year |
---|---|
[Inhibitors of the receptor A for endothelin-1].
Topics: Atrasentan; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2010 |